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Patients taking direct oral anticoagulants (DOACs) who then need an emergency invasive procedure require
specialized management strategies. Appropriate patient evaluation includes assessment of the current
anticoagulation state, including timing of the last dose. DOACs require particular coagulation assays to
measure anticoagulation levels accurately, although standard coagulation screening tests may provide
qualitative guidance. Specialty societies have endorsed general recommendations for patient management
to promote hemostasis in anticoagulated patients requiring surgery or other invasive procedures. These
include general stopping rules (such as 24 hours for low-risk procedures and 48 hours for high-risk
surgery with normal renal function) for elective procedures. Bridging therapy when oral anticoagulant
treatment is interrupted has recently been questioned, depending on the clinical scenario. Novel agents for
the reversal of DOAC-induced anticoagulation have recently been developed. Idarucizumab, a humanized
monoclonal antibody fragment that selectively binds dabigatran, was recently approved for clinical use in
patients with life-threatening or uncontrolled bleeding, and for patients requiring emergency interventions.
Idarucizumab can streamline the pre- and periprocedural anticoagulation management of dabigatran-treated
patients, as it provides fast, complete, and sustainable reversibility. Andexanet alfa is an inactive, decoy
factor Xa (FXa) molecule that binds FXa inhibitors, and ciraparantag is a synthetic molecule designed to
bind fractionated and unfractionated heparins, and each of the currently approved DOACs. As clinical
development of the additional anti-FXa-speciﬁc anticoagulant reversal agents proceeds, the respective role
of each in the management of emergency bleeding events and invasive procedures will be better deﬁned,
and it is hoped they will make important contributions to patient care.
 2016 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
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allows estimation of the time required for elimination from
the plasma, and is therefore an important consideration.
Plasma concentrations of anticoagulants generally decrease
to minimally effective levels within 3-5 half-lives, but the
exact timing may vary depending upon the agent and the
patient’s overall clinical status. Recommendations based on
pharmacokinetic and pharmacodynamic studies have been
made about the optimal time for stopping DOAC-related
anticoagulation.5-8 In addition, a patient’s renal function is
an important consideration for elimination of most of the
DOACs, especially dabigatran, because lower creatinine
clearance (CrCl) rates are associated with elevated serum
concentrations.9,10 Potential interactions with concomitant
medications must also be considered, although for the most
part, the DOACs are reported to have fewer drugedrug
interactions than do the vitamin K antagonists (VKAs).5-8
The management of patients who are treated with
DOACs and later require an emergency procedure due to
trauma or other emergencies continues to evolve with the
development of experience and deﬁnitive management
strategies. This brief review will discuss topics known to
impact clinical care in DOAC-treated patients who require
surgery or invasive procedures, including assessing
the current anticoagulation effect, their periprocedural
management, current protocols for temporary discontinua-
tions in DOAC therapy, and the utility of particular DOAC
reversal agents.MEASUREMENT OF ANTICOAGULATION WITH THE
DOACS
Routine monitoring of anticoagulation is not generally
recommended or required for patients treated with any of the
approved DOACs. However, in patients who are in need of
an emergency surgical or invasive procedure, an on-demand
assessment of the current level of anticoagulation effect is
important.11,12 It should be kept in mind that key information
to guide the interpretation of results from individual
coagulation tests in these patients includes timing of the last
dose of the speciﬁc anticoagulant and the patient’s renal
function.11
There are a number of general considerations when
assessing the anticoagulation effects of individual DOACs,
including the individual drug in question, and the relevant
coagulation assay that should be used to assess its effects. The
international normalized ratio (INR) was developed to
monitor anticoagulation associated with the VKAs, and is not
as reliable an assay for the assessment of the anticoagulant
effects of some factor Xa (FXa) inhibitors (apixaban)
or dabigatran.13 The prothrombin time (PT) may provide a
potential indication of the anticoagulant effects of FXa
inhibitors, but the assay is relatively insensitive.13
For example, the PT is not sufﬁciently sensitive to reliably
measure apixaban levels in therapeutic ranges.14,15 Similar
results have been reported when the PT assay has been used
to assess anticoagulation with rivaroxaban, where PTresults correlated poorly with rivaroxaban concentrations.16
In addition, results of this assay can vary depending on the
batch of individual reagents used to process the samples.13,16
Specialized anti-FXa assays, which are distinct from
those used for low-molecular-weight heparin (LMWH),
have been developed recently and are recommended for
quantitative measurements of rivaroxaban and apixaban17,18
and edoxaban.7 However, for optimal performance and
accuracy, these assays will require individual calibration to
each speciﬁc drug.13,16
The PT assay is generally not sensitive enough to reliably
measure clinically relevant dabigatran concentrations, but
responses may be increased with high levels of dabigatran.15
A normal activated partial thromboplastin time assay can be
used as a screening tool to determine a potential anti-
coagulation effect due to dabigatran, although this is not the
most sensitive assay available.13 The thrombin time is a
sensitive assessment of dabigatran anticoagulation, but this
assay can overestimate dabigatran levels at high concentra-
tions and is, therefore, most useful as a qualitative tool.13
The dilute thrombin time (dTT), as measured by the
HEMOCLOT assay (HYPHEN BioMed, Neuville-sur-Oise,
France), best correlates with dabigatran plasma concentra-
tions and is, therefore, a more reliable measure of the
anticoagulant effect of dabigatran. However, this assay is not
currently approved in the United States.13,19 In the European
Union, measuring dTT with the calibrated HEMOCLOT
thrombin inhibitor assay is recommended as the tool of
choice for assessing the anticoagulation effect of dabiga-
tran.20 Also in EU, the ecarin clotting time assay is often used
in a fashion similar to the dTT to assess anticoagulant effects
of dabigatran.21 A summary of the coagulation assays for
each approved agent is provided in Table 1.5-8,17,20,22PERIPROCEDURAL MANAGEMENT
A recent analysis from the Randomized Evaluation of Long-
term anticoagulation therapY (RE-LY) study (dabigatran vs
VKA in patients with NVAF) reported similar rates of
perioperative bleeding and thromboembolism in warfarin-
and dabigatran-treated patients.23 Similar results have also
been reported in studies of “real-world” populations at high
risk for thromboembolic and bleeding events for dabiga-
tran24 and rivaroxaban25 in general clinical practice.
Clinical decisions about the management of DOAC-treated
patients who require an invasive procedure should be based in
part on the patient’s renal function, the length of time from last
DOAC administration, concomitant medications that the pa-
tient is taking, and their overall risk of procedural bleeding.26
For example, in patients with moderate renal impairment
(CrCl 30-50 mL/min), medications such as the P-glycoprotein
(P-gp) inhibitors dronedarone or systemic ketoconazole may
increase exposure to dabigatran and potentially lead to
hemostatic dysfunction.5 Similar concerns have been raised
for co-administration of FXa inhibitors and agents that are
strong dual inhibitors of Cytochrome P450 3A4 and P-gp (eg,
ketoconazole, itraconazole, ritonavir, and clarithromycin for
Table 1 Appropriateness of Assays for Monitoring the Activity of Direct Oral Anticoagulants5-8,17,20,22
Drug
Quantitative Assays
(Provide an Estimate of
Anticoagulant Drug Levels)
Qualitative Assays
(Indicate Presence or
Absence of Drug Effect) Not Recommended
Direct FXa inhibitors
(apixaban, rivaroxaban,
or edoxaban)
Speciﬁc, calibrated anti-FXa
assays
Prothrombin time assay obtained
in seconds with sensitive
reagents
Insensitive prothrombin time, activated
partial thromboplastin time, dilute
thrombin time or thrombin time
assays, or heparin-speciﬁc assays
such as the activated clotting time
assay
Direct thrombin
inhibitor (dabigatran)
HEMOCLOT dilute thrombin assay,
ecarin clotting time
Activated partial thromboplastin
time, thrombin time, activated
clotting time assay
Chromogenic anti-FXa assays
FXa ¼ factor Xa.
Levy Discontinuation of DOACs S49apixaban)6; and diltiazem, verapamil, dronedarone, and
erythromycin for rivaroxaban.8 Co-administration of P-gp
inhibitors such as amiodarone, cyclosporine, dronedarone,
erythromycin, ketoconazole, quinidine, and verapamil has
been reported to increase edoxaban exposure.7 Concomitant
use of rifampin, a P-gp inducer, is also contraindicated in
patients treated with edoxaban.7
Recommendations for DOAC treatment interruption
have been made previously, especially for surgical patients,
and are summarized below. The European Society of
Anaesthesiology and the French Working Group on Peri-
operative Haemostasis (GIHP) recommend interruption of
DOAC therapy w24 hours (2 or 3 half-lives) prior to a
procedure that carries a low bleeding risk, but 5 days prior to
an intervention with a medium or high bleeding risk,
dependent on the DOAC and factors such as the patient’s
renal function.27,28 The European Heart Rhythm Associa-
tion’s guide to DOAC use suggests a general stopping rule
of 24 hours for low-risk procedures and 48 hours for
high-risk surgery. However, longer delays are suggested for
patients with a CrCl of <80 mL/min taking dabigatran and
those with a CrCl of 15-30 mL/min who are administered
FXa inhibitors.26 Other expert consensus documents
recommend at least a 24e48-hour discontinuation window
for a particular DOAC based on the speciﬁc agent, renal
function, and high vs low risk of procedural bleeding.29
Speciﬁc guidance for discontinuation and bridging for
each approved agent are presented in Table 2.5-8,30-33 It is
important to keep in mind that additional studies to assess
standardized perioperative management protocols in
DOAC-treated patients are ongoing, and the results from
these studies are expected to reﬁne our understanding of this
clinical challenge.29,34INTERRUPTION OF ORAL ANTICOAGULATION
AND BRIDGING/SWITCHING BETWEEN
ANTICOAGULANTS
Earlier guidelines for periprocedural management of patients
on oral anticoagulation supported the discontinuation of oralanticoagulation with warfarin and recommended the use of
LMWH or unfractionated heparin to bridge patients with
atrial ﬁbrillation who are at elevated risk for thromboembolic
events.35,36 More recently, the need for anticoagulant bridging
to allow invasive procedures to continue has been called into
question.37,38 In fact, current guidelines from the American
Academy of Neurology state that bridging therapy with
heparin is probably associated with an increased bleeding risk
when compared with warfarin discontinuation.39 These rec-
ommendations are supported by a recent report from the
BRIDGE Investigators, who state that stopping warfarin
(without bridging with LMWH), was noninferior to bridging
therapy when warfarin treatment was interrupted for an
elective operation or other elective invasive procedure.40
Similar guidance is emerging for patients who are anti-
coagulated with any of the currently approved DOACs,
where the limited data available suggest that bridging with
another anticoagulant provides limited, if any, beneﬁt to the
patient. An example of this can be found in a recent
sub-analysis of data from the RE-LY study, where
dabigatran-treated patients who had treatment interruption
for an elective procedure experienced more major bleeding
events with bridging therapy than patients who did not
receive bridging therapy, with no signiﬁcant effect on
arterial thromboembolism.41 Anticoagulation with dabiga-
tran should begin as soon after the procedure as is medi-
cally possible.5 Related guidance is also provided by the
manufacturer of apixaban6 and also does not recommend
bridging therapy during DOAC treatment interruptions. For
patients on either edoxaban7 or rivaroxaban,8 treatment
should be stopped at least 24 hours prior to an invasive or
surgical procedure. A parenteral anticoagulant can be
administered if needed until an oral anticoagulant can be
re-administered.
There is ongoing interest about the clinical need for
bridging therapy with heparin or other parenteral agents
during DOAC treatment interruptions for invasive or sur-
gical procedures. Randomized and controlled clinical trials
currently underway, such as the BRUISE CONTROL-2, are
expected to provide evidence-based clinical guidance for the
Table 2 Discontinuation Guidance
Apixaban6,30,31 Dabigatran5,30,32 Edoxaban7,30,31 Rivaroxaban8,30,33
Discontinuation for
surgery or other
interventions
In cases where there is a
low risk of bleeding or
when a potential
bleeding event would be
in an easily controlled
noncritical location,
apixaban should be
discontinued at least
24 h prior to elective
surgery or invasive
procedures.
In cases with a moderate
or high risk of
unacceptable or
clinically signiﬁcant
bleeding, apixaban
should be discontinued
at least 48 h prior to
elective surgery or
invasive procedures.
Dabigatran should be
discontinued 1-2 d
(CrCl of 50 mL/min) or
3-5 d (CrCl of <50 mL/
min) in advance of any
invasive or surgical
procedures.
For patients who require
complete hemostasis,
such as those
undergoing major
surgery, spinal
puncture, or placement
of a spinal or epidural
catheter or port, longer
discontinuation times
should be considered.
Use of idarucizumab, a
speciﬁc dabigatran
anticoagulation reversal
agent, should be
considered in cases
where emergency
surgery or urgent
procedures are needed.
Edoxaban should be
discontinued at least
24 h prior to invasive or
surgical procedures
because of the risk of
bleeding.
If anticoagulation must be
discontinued to reduce
the risk of bleeding with
surgical or other
procedures, rivaroxaban
should be stopped at
least 24 h prior to the
procedure to reduce the
risk of bleeding.
Bridging Bridging anticoagulation
is generally not required
during the 24-48 h after
stopping apixaban in
advance of a procedure.
If dabigatran is
discontinued for other
than pathological
bleeding or completion
of a course of therapy,
consider coverage with
another anticoagulant,
and then restart
dabigatran as soon as
medically appropriate.
Administer a parenteral
anticoagulant and then
switch to oral edoxaban
if oral medication
cannot be taken during
or after surgical
intervention.
If oral medication cannot
be taken during or after
surgical intervention,
consider administering
a parenteral
anticoagulant.
Speciﬁc reversal agent Speciﬁc FXa reversal agent
(andexanet alfa) is
under accelerated
development and FDA
review.
Ciraparantag, an agent to
reverse the
anticoagulant effects of
both LMWH and UFH,
and all 4 currently
approved DOACs is
currently under
development.
Use the approved and
available speciﬁc
reversal agent
(idarucizumab) in case
of emergency surgery or
urgent procedures when
reversal of the
anticoagulant effect of
dabigatran is needed.
Ciraparantag, an agent to
reverse the
anticoagulant effects of
both LMWH and UFH,
and all 4 currently
approved DOACs, is
currently under
development.
Speciﬁc FXa reversal agent
(andexanet alfa) is
under accelerated
development and FDA
review.
Ciraparantag, an agent to
reverse the
anticoagulant effects of
both LMWH and UFH,
and all 4 currently
approved DOACs is
currently under
development.
Speciﬁc FXa reversal agent
(andexanet alfa) is
under accelerated
development and FDA
review.
Ciraparantag, an agent to
reverse the
anticoagulant effects of
both LMWH and UFH,
and all 4 currently
approved DOACs is
currently under
development.
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Table 2 Continued
Apixaban6,30,31 Dabigatran5,30,32 Edoxaban7,30,31 Rivaroxaban8,30,33
Restarting DOAC As soon as adequate
hemostasis has been
established after any
surgical or other
procedure, apixaban
should be restarted.
Restart dabigatran as soon
as medically
appropriate, or 24 h
after idarucizumab
reversal.
Edoxaban can be restarted
after the surgical or
other procedure as soon
as adequate hemostasis
has been established
noting that the time to
onset of
pharmacodynamic effect
is 1-2 h.
Rivaroxaban should be
re-started after any
invasive procedures as
soon as appropriate
hemostasis is
established. It should
be noted that the time
to onset of therapeutic
effect is brief.
Warnings Premature discontinuation
of apixaban increases
the risk of thrombotic
events.
Epidural or spinal
hematomas may occur
in patients treated with
apixaban who are
receiving neuraxial
anesthesia or
undergoing spinal
puncture.
An increased rate of stroke
was observed during the
transition from
apixaban to warfarin in
clinical trials in atrial
ﬁbrillation patients.
Premature discontinuation
of any oral
anticoagulant,
including dabigatran,
increases the risk of
thrombotic events.
Epidural or spinal
hematomas may occur
in patients treated with
dabigatran who are
receiving neuraxial
anesthesia or
undergoing spinal
puncture.
Edoxaban has reduced
efﬁcacy in NVAF
patients with a CrCl of
>95 mL/min, and
should not be used in
this population.
Premature discontinuation
of edoxaban increases
the risk of ischemic
events.
Epidural or spinal
hematomas may occur
in patients treated with
edoxaban who are
receiving neuraxial
anesthesia or
undergoing spinal
puncture.
Premature discontinuation
of any oral
anticoagulant,
including rivaroxaban,
increases the risk of
thrombotic events.
Epidural or spinal
hematomas have
occurred in patients
treated with rivaroxaban
who are receiving
neuraxial anesthesia or
undergoing spinal
puncture.
CrCl ¼ creatine clearance; DOAC ¼ direct oral anticoagulant; FDA ¼ U.S. Food and Drug Administration; FXa ¼ factor Xa; LMWH ¼ low-molecular-weight
heparin; NVAF ¼ nonvalvular atrial ﬁbrillation; UFH ¼ unfractionated heparin.
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invasive or surgical procedures.42REVERSAL OF DOAC-INDUCED
ANTICOAGULATION WITH SPECIFIC AGENTS
Several reversal agents to rapidly counter the anticoagulation
effects of DOACs are in development, and the respective roles
for each will eventually be deﬁned through formal studies and
clinical experience. A speciﬁc reversal agent for dabigatran,
idarucizumab, is a humanized monoclonal antibody that
selectively binds dabigatran and reverses dabigatran-induced
anticoagulation. In the RE-VERSE AD (A Study of
the RE-VERSal Effects of Idarucizumab onActive Dabigatran)
study, idarucizumab reversed the anticoagulant effects of
dabigatran in patients with a major bleeding event, or whowere
in need of an urgent invasive procedure (within 8 hours).22,43
Idarucizumab has recently been approved by the U.S. Food
and Drug Administration and the EuropeanMedicines Agency
for the reversal of dabigatran-related anticoagulation in cases
where emergency surgery or urgent procedures are required, or
in cases of life-threatening or uncontrolled bleeding.32
Andexanet alfa is in advanced clinical trials as a
speciﬁc reversal agent of FXa inhibitors, includingapixaban, edoxaban, and rivaroxaban, and enox-
aparin.44,45 However, it should be noted that clinical trial
data have not yet been published where andexanet alfa
was studied for the reversal of anticoagulation in surgical
patients, where emergency surgery or urgent procedures
are required, or in cases of life-threatening or uncontrolled
bleeding. Andexanet alfa is a bioengineered human FXa
decoy protein that has been modiﬁed to delete the native
catalytic activity while retaining the high-afﬁnity binding
of FXa inhibitors within the enzymatic active site. By
binding to circulating FXa inhibitors, andexanet alfa
makes endogenous FXa available to contribute to the
coagulation cascade.45
Another potential approach is ciraparantag (PER977), a
small cationic and water-soluble molecule that was designed
to bind with high afﬁnity to unfractionated heparin and
LMWH by forming noncovalent hydrogen bonds and strong
chargeecharge interactions.30 Ciraparantag binds in a
similar way to the oral FXa inhibitors, edoxaban, rivarox-
aban, and apixaban, and to the oral thrombin inhibitor
dabigatran, potentially achieving potent and rapid reversal
of their anticoagulant effects.30
As clinical experience with the reversal agents grows, the
respective role of each reversal agent in the management of
S52 The American Journal of Medicine, Vol 129, No 11A, November 2016emergency bleeding events and surgical procedures will be
better deﬁned over the next few years, leading to important
contributions in the care of patients with NVAF and other
thromboembolic challenges.46References
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